First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)

Ken Kato, Yuichiro Doki, Takashi Ogata, Satoru Motoyama, Hisato Kawakami, Masaki Ueno, Takashi Kojima, Yasuhiro Shirakawa, Morihito Okada, Ryu Ishihara, Yutaro Kubota, Carlos Amaya-Chanaga, Tian Chen, Yasuhiro Matsumura, Yuko Kitagawa

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Fingerprint

Dive into the research topics of 'First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)'. Together they form a unique fingerprint.

Medicine & Life Sciences